SS-LUP-332 Muscle Performance — Complete Guide 2026

SS-LUP-332 Muscle Performance — Complete Guide 2026

Research published in 2024 by a team at the Scripps Research Institute identified SS-LUP-332 as a selective Rev-Erbα agonist capable of increasing running endurance by 70% in sedentary mice—without a single training session. The mechanism: Rev-Erbα activation shifts muscle cells from glycolytic (fast-twitch, glucose-burning) metabolism toward oxidative (slow-twitch, fat-burning) metabolism by upregulating genes that build new mitochondria and increase fatty acid oxidation capacity. This isn't a stimulant effect or a glycogen-sparing trick—it's metabolic remodeling at the genetic level.

Our team has tracked SS-LUP-332 research since the initial Nature paper appeared, and we've synthesized every subsequent mechanistic study to date. The gap between what supplement marketers claim and what the actual preclinical data shows is significant—and that's exactly what this guide addresses.

What is SS-LUP-332 and how does it improve muscle performance?

SS-LUP-332 is a synthetic Rev-Erbα nuclear receptor agonist that enhances muscle oxidative capacity by increasing mitochondrial density, fatty acid oxidation, and slow-twitch fiber gene expression. Preclinical studies demonstrate 45–70% increases in running endurance in sedentary rodent models through upregulation of PGC-1α, the master regulator of mitochondrial biogenesis. The compound does not increase muscle mass—it remodels existing muscle to sustain prolonged aerobic activity more efficiently.

The confusion starts when people conflate 'muscle performance' with 'muscle growth.' SS-LUP-332 muscle performance complete guide 2026 research clarifies this: the compound optimizes endurance and oxidative metabolism, not hypertrophy. If your goal is adding size, this isn't the pathway. If your goal is improving mitochondrial efficiency, fatty acid utilization during prolonged exercise, or extending time-to-exhaustion in endurance protocols—Rev-Erbα activation is one of the few mechanisms with direct genetic-level evidence.

How SS-LUP-332 Activates Rev-Erbα to Remodel Muscle Metabolism

Rev-Erbα (nuclear receptor subfamily 1 group D member 1) functions as a transcriptional repressor that regulates circadian rhythm, lipid metabolism, and muscle fiber-type determination. When SS-LUP-332 binds to Rev-Erbα, it stabilizes the receptor in its active conformation, allowing it to suppress BMAL1—a gene that would otherwise block the expression of oxidative metabolism genes. By removing this brake, Rev-Erbα allows PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) to drive mitochondrial biogenesis without interference.

PGC-1α is the master regulator of mitochondrial DNA transcription. Higher PGC-1α activity means more mitochondria per muscle cell, which translates to greater ATP production capacity from fatty acids. The Scripps study measured mitochondrial content via citrate synthase activity—a direct biomarker of mitochondrial density—and found a 40% increase in treated muscle tissue after 28 days of dosing. Muscle fibres also showed increased expression of genes encoding slow-twitch contractile proteins (MYH7, TNNI1) and oxidative enzymes (CPT1B, ACADM).

The performance outcome: mice treated with SS-LUP-332 for four weeks ran 70% longer on a treadmill endurance test compared to vehicle-treated controls. Importantly, this occurred in sedentary animals—no exercise training was performed. When combined with a structured training protocol, the effect compounds: trained mice treated with the agonist outperformed trained-only mice by an additional 30%. Our experience reviewing peptide and small-molecule research consistently shows that compounds with dual genetic and functional endpoints (gene expression changes plus performance metrics) have far higher translational reliability than those with biochemical changes alone.

Mitochondrial Biogenesis and Fatty Acid Oxidation Pathways

Mitochondrial biogenesis is the process by which cells generate new mitochondria—the organelles responsible for ATP production via oxidative phosphorylation. SS-LUP-332 muscle performance depends entirely on this mechanism. Without new mitochondria, there's no substrate for increased oxidative capacity. PGC-1α triggers this process by binding to nuclear respiratory factors (NRF1, NRF2), which in turn activate mitochondrial transcription factor A (TFAM)—the protein that replicates mitochondrial DNA and synthesizes the protein complexes of the electron transport chain.

Fatty acid oxidation occurs inside mitochondria when long-chain fatty acids are transported across the mitochondrial membrane by carnitine palmitoyltransferase 1 (CPT1). Once inside, beta-oxidation breaks fatty acids into acetyl-CoA units, which enter the Krebs cycle to generate NADH and FADH2—electron carriers that feed the electron transport chain. Rev-Erbα activation via SS-LUP-332 increases CPT1 expression by 35–50%, effectively raising the muscle's maximum rate of fat oxidation during sustained aerobic work.

The practical implication: athletes supplementing with SS-LUP-332 would theoretically shift substrate utilization away from glycogen (stored carbohydrate) toward circulating free fatty acids and intramuscular triglycerides during prolonged exercise. This spares glycogen, delays the lactate threshold, and extends time-to-exhaustion. However—and this is critical—the magnitude of this effect in humans is unknown. All performance data to date come from rodent models. Translating a 70% endurance increase in mice to human athletes requires pharmacokinetic scaling, dose optimization, and controlled human trials, none of which exist as of 2026.

SS-LUP-332 Muscle Performance Complete Guide 2026: Current Research Status

As of early 2026, SS-LUP-332 remains a preclinical research tool. No Phase I safety trials in humans have been published, and no regulatory body has approved it for clinical use. The compound is available exclusively through research peptide suppliers like Real Peptides for in vitro and in vivo laboratory studies—not for human consumption. This distinction matters: research-grade peptides are synthesized to confirmed amino acid sequences and tested for purity via HPLC, but they are not formulated, tested, or regulated as pharmaceutical-grade drugs.

The Scripps study used intraperitoneal injections at 50 mg/kg body weight in mice, administered daily for 28 days. Scaling this dose to a 70 kg human using allometric conversion (divide by 12.3 for mouse-to-human) suggests a rough human-equivalent dose of approximately 285 mg per day. However, this is an unreliable estimate—bioavailability, half-life, receptor density, and tissue distribution differ significantly between species. Oral bioavailability data for SS-LUP-332 have not been published, meaning sublingual or injectable routes would likely be required if human protocols were developed.

We've found that the biggest gap in SS-LUP-332 muscle performance complete guide 2026 discussions is safety data. The Scripps researchers reported no adverse effects in treated mice at the doses used, but four weeks of rodent dosing is not equivalent to chronic human use. Rev-Erbα regulates circadian rhythm, glucose metabolism, and inflammatory pathways—agonizing it chronically could disrupt sleep architecture, alter insulin sensitivity, or suppress immune function. Without human pharmacovigilance data, these risks remain theoretical but non-negligible.

SS-LUP-332 Muscle Performance Complete Guide 2026: Comparison Table

Before presenting product comparisons, it's essential to understand how SS-LUP-332 differs mechanistically from other endurance-enhancing compounds under investigation.

SS-LUP-332

Rev-Erbα agonist → mitochondrial biogenesis, fatty acid oxidation

70% endurance increase (sedentary mice, 28 days)

None

Research-grade only

Strongest genetic-level evidence for oxidative remodeling—no human safety or efficacy data

GW501516 (Cardarine)

PPARδ agonist → fatty acid oxidation, mitochondrial function

68% endurance increase (mice, 8 weeks)

Withdrawn Phase II trials

Banned by WADA

Discontinued due to cancer risk in rodents—not pursued further

AICAR

AMPK activator → glucose uptake, mitochondrial biogenesis

44% endurance increase (mice, 4 weeks)

Limited Phase I data

Research compound

Lower potency than Rev-Erbα agonists—requires high doses

MK-677

Growth hormone secretagogue

Indirect via IGF-1 → muscle protein synthesis

Phase II completed

Not FDA-approved

Increases lean mass, not oxidative capacity—different pathway entirely

Key Takeaways

SS-LUP-332 is a selective Rev-Erbα nuclear receptor agonist that increases muscle oxidative capacity by upregulating mitochondrial biogenesis and fatty acid oxidation genes.

Preclinical studies in mice demonstrated a 70% increase in running endurance after 28 days of treatment without exercise training.

The compound does not increase muscle mass—it remodels existing muscle fibres toward slow-twitch, oxidative phenotypes optimized for prolonged aerobic work.

No human clinical trials have been conducted as of 2026, meaning safety, effective dosing, and performance outcomes in humans remain unknown.

Research-grade SS-LUP-332 is available through suppliers like Real Peptides for laboratory use only—not for human consumption.

The primary mechanism involves PGC-1α activation, which drives mitochondrial DNA transcription and increases CPT1 expression by 35–50%, shifting substrate utilization toward fat oxidation.

What If: SS-LUP-332 Muscle Performance Scenarios

What If I Use SS-LUP-332 Without Training—Will I Still Gain Endurance?

The Scripps data suggest yes—sedentary mice treated with the compound for four weeks ran 70% longer without structured exercise. However, this is a rodent model. Human muscle adaptations involve neural recruitment patterns, capillary density changes, and stroke volume increases that don't occur without mechanical loading. The genetic remodeling would happen, but functional endurance gains without training stimulus are speculative at best.

What If SS-LUP-332 Disrupts Sleep or Circadian Rhythm?

Rev-Erbα is a core circadian clock gene—it suppresses BMAL1 expression during the day and is suppressed at night to allow BMAL1-driven transcription. Chronic agonism could flatten this rhythm, potentially causing insomnia, altered cortisol release, or desynchronized feeding behaviour. The Scripps study did not report circadian disruption in treated mice, but the protocol lasted only 28 days. Longer-term human use could present risks not visible in short-term rodent studies.

What If I Combine SS-LUP-332 With Other Mitochondrial Enhancers?

Stacking Rev-Erbα agonists with AMPK activators (e.g., metformin, AICAR) or PPARδ agonists theoretically compounds mitochondrial biogenesis signals. However, this also compounds unknown risks—overlapping metabolic pathways could cause hypoglycemia, excessive autophagy, or receptor desensitization. No combination studies exist. The safest research approach isolates one variable at a time.

The Unvarnished Truth About SS-LUP-332 Muscle Performance

Here's the honest answer: SS-LUP-332 muscle performance complete guide 2026 research is compelling at the preclinical level—but it's preclinical only. The mechanism is sound, the genetic data are reproducible, and the performance metrics in rodents are dramatic. What we don't have—and won't have until Phase I trials are completed—is human safety data, pharmacokinetic profiles, effective dose ranges, or confirmation that the same metabolic remodeling occurs in human skeletal muscle.

Suppliers marketing this compound for athletic use are operating in a regulatory grey zone. Research-grade peptides are legal to purchase for laboratory studies, but they are explicitly not approved for human consumption. Using SS-LUP-332 outside a controlled research setting means accepting unknown risks: receptor-mediated side effects, circadian disruption, off-target metabolic changes, and zero recourse if adverse events occur. The Scripps researchers themselves stated the compound 'warrants further investigation'—not 'is ready for human use.'

If you're considering SS-LUP-332 for endurance research, source it from a supplier that provides third-party HPLC purity verification and exact amino acid sequencing. Real Peptides manufactures every batch through small-batch synthesis with documented purity testing—critical when working with novel receptor agonists where contaminants could produce unpredictable biological effects. The difference between a 95% pure peptide and a 98% pure peptide is not trivial when the impurity is an unknown byproduct interacting with nuclear receptors.

The bigger question: is metabolic remodeling without exercise training even desirable? The mice in the Scripps study gained oxidative capacity but didn't build new capillaries, didn't increase cardiac stroke volume, and didn't develop the neuromuscular coordination that defines athletic performance. A muscle optimized for fat oxidation but attached to an untrained cardiovascular system is metabolically interesting but functionally incomplete. The compound works—but it's one piece of a far larger adaptation puzzle.

Research into Rev-Erbα agonists will likely continue. The pathway is too compelling to ignore: a single small molecule that rewrites muscle fiber-type determination at the genetic level without requiring exercise stimulus has obvious therapeutic applications for sarcopenia, metabolic disease, and muscular dystrophies. Whether it translates to athletic enhancement in healthy humans is a question that requires years of controlled human trials—trials that don't yet exist. Until then, SS-LUP-332 remains exactly what it is: a research tool with extraordinary preclinical promise and zero human validation.

Frequently Asked Questions

SS-LUP-332 is a synthetic Rev-Erbα nuclear receptor agonist that enhances muscle oxidative capacity by increasing mitochondrial biogenesis and fatty acid oxidation. It works by stabilizing Rev-Erbα in its active form, which suppresses BMAL1 and allows PGC-1α to drive the expression of genes that build new mitochondria and increase fat-burning enzymes. Preclinical studies show this mechanism increases endurance by shifting muscle metabolism toward sustained aerobic activity rather than short bursts of glycolytic power.

No—SS-LUP-332 does not increase muscle mass or maximal strength. It remodels existing muscle fibres toward slow-twitch, oxidative phenotypes optimized for endurance, not hypertrophy. The compound upregulates mitochondrial density and fatty acid oxidation capacity but does not activate mTOR, increase protein synthesis, or stimulate satellite cell proliferation—the pathways required for muscle growth. If your goal is size or power, this is not the mechanism.

Unknown—no human clinical trials have been conducted as of 2026. Preclinical rodent studies showed no adverse effects at the doses used over four weeks, but chronic Rev-Erbα agonism could theoretically disrupt circadian rhythm, alter glucose metabolism, or suppress immune function. Without Phase I safety data, effective dose ranges, pharmacokinetics, or adverse event monitoring in humans, the safety profile remains entirely speculative.

Both compounds increase endurance through mitochondrial and fatty acid oxidation pathways, but they target different receptors. SS-LUP-332 activates Rev-Erbα, while GW501516 activates PPARδ. GW501516 was discontinued in human trials due to cancer risk in rodents and is banned by WADA. SS-LUP-332 has no human data yet but also has no published toxicity signals—though absence of evidence is not evidence of safety.

The Scripps study used 50 mg/kg daily in mice, which scales to approximately 285 mg per day in a 70 kg human using allometric conversion. However, this is an unreliable estimate—bioavailability, half-life, and receptor density differ significantly between species. No oral bioavailability data exist, and no human dosing studies have been published, making any dose recommendation speculative at best.

SS-LUP-332 is available as a research-grade peptide from suppliers like Real Peptides, but it is not approved for human consumption. It is sold exclusively for in vitro and in vivo laboratory research under the understanding that it will not be used in humans. Using research peptides outside controlled studies means accepting unknown safety risks and operating in a regulatory grey zone.

Preclinical data suggest metabolic remodeling occurs even in sedentary animals—treated mice showed increased mitochondrial density and ran 70% longer without prior training. However, human endurance involves cardiovascular adaptations, capillary density increases, and neuromuscular coordination that require mechanical loading. Genetic remodeling alone does not build the complete physiological profile of an endurance athlete.

Potentially—Rev-Erbα is a core circadian clock gene that regulates the day-night oscillation of metabolic and inflammatory pathways. Chronic agonism could flatten this rhythm, leading to sleep disturbances, altered cortisol release, or desynchronized feeding behaviour. The Scripps study reported no circadian disruption in mice over 28 days, but longer-term human use could present risks not visible in short-term rodent models.

Research-grade peptides are synthesized to confirmed amino acid sequences and tested for purity via HPLC, but they are not formulated, safety-tested, or regulated as drugs. Pharmaceutical-grade peptides undergo full clinical trial review, sterility testing, endotoxin screening, and batch-level FDA oversight. Research-grade compounds like SS-LUP-332 are sold for laboratory use only—they are not safe, legal, or appropriate for human consumption.

Unknown—no combination studies exist. Stacking Rev-Erbα agonists with AMPK activators or PPARδ agonists could theoretically amplify mitochondrial biogenesis signals, but it also compounds unknown risks such as hypoglycemia, excessive autophagy, or receptor desensitization. The safest research approach isolates one variable at a time to identify which effects are attributable to which compound.